Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Testing and Detection During Peripartum Hospitalizations Among a Multicenter Cohort of Pregnant Persons: March 2020-February 2021

被引:1
|
作者
Delahoy, Miranda J. [1 ,2 ]
Munoz, Flor [3 ]
Li, De-Kun [4 ]
Arriola, Carmen Sofia [1 ]
Bond, Nanette Lee [3 ]
Daugherty, Michael [1 ]
Ferber, Jeannette [4 ]
Ferguson, Nickolas [5 ]
Hadden, Louise [5 ]
Henderson, Jillian T. [6 ]
Irving, Stephanie A. [6 ]
Juergens, Mary [5 ]
Kancharla, Venkatesh [3 ]
Greenberg, Mara [7 ]
Odouli, Roxana [4 ]
Newes-Adeyi, Gabriella [5 ]
Nicholson, Erin G. [3 ]
Reichle, Lawrence [5 ]
Sanyang, Momodou [3 ]
Snead, Margaret [1 ]
Dawood, Fatimah S. [1 ]
Naleway, Allison L. [6 ]
机构
[1] Ctr Dis Control & Prevent, COVID 19 Response Team, Atlanta, GA 30329 USA
[2] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30329 USA
[3] Baylor Coll Med, Houston, TX 77030 USA
[4] Kaiser Permanente Northern Calif, Oakland, CA USA
[5] Abt Associates Inc, Rockville, MD USA
[6] Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR USA
[7] Kaiser Permanente Oakland Med Ctr, Dept Obstet & Gynecol, Oakland, CA USA
关键词
COVID-19; pregnancy; neonate; SARS-CoV-2; testing; OUTCOMES; INFECTION; STATES;
D O I
10.1093/cid/ciac657
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background Identifying severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections during peripartum hospitalizations is important to guide care, implement prevention measures, and understand infection burden. Methods This cross-sectional analysis used electronic health record data from hospitalizations during which pregnancies ended (peripartum hospitalizations) among a cohort of pregnant persons at 3 US integrated healthcare networks (sites 1-3). Maternal demographic, medical encounter, SARS-CoV-2 testing, and pregnancy and neonatal outcome information was extracted for persons with estimated delivery and pregnancy end dates during March 2020-February 2021 and >= 1 antenatal care record. Site-stratified multivariable logistic regression was used to identify factors associated with testing and compare pregnancy and neonatal outcomes among persons tested. Results Among 17 858 pregnant persons, 10 863 (60.8%) had peripartum SARS-CoV-2 testing; 222/10 683 (2.0%) had positive results. Testing prevalence varied by site and was lower during March-May 2020. Factors associated with higher peripartum SARS-CoV-2 testing odds were Asian race (adjusted odds ratio [aOR]: 1.36; 95% confidence interval [CI]: 1.03-1.79; referent: White) (site 1), Hispanic or Latino ethnicity (aOR: 1.33; 95% CI: 1.08-1.64) (site 2), peripartum Medicaid coverage (aOR: 1.33; 95% CI: 1.06-1.66) (site 1), and preterm hospitalization (aOR: 1.69; 95% CI: 1.19-2.39 [site 1]; aOR: 1.39; 95% CI: 1.03-1.88 [site 2]). Conclusions Findings highlight potential disparities in SARS-CoV-2 peripartum testing by demographic and pregnancy characteristics. Testing practice variations should be considered when interpreting studies relying on convenience samples of pregnant persons testing positive for SARS-CoV-2. Efforts to address testing differences between groups could improve equitable testing practices and care for pregnant persons with SARS-CoV-2 infections. Data collected from a pregnancy cohort during March 2020-February 2021 indicate peripartum SARS-CoV-2 testing practices during hospitalizations varied by individual and pregnancy characteristics despite universal testing protocols, highlighting potential testing disparities and missed opportunities for infection prevention and treatment.
引用
收藏
页码:E51 / E59
页数:9
相关论文
共 50 条
  • [21] Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and glial cells: Insights and perspectives
    Vargas, Gabriele
    Geraldo, Luiz Henrique Medeiros
    Salomao, Natalia Gedeao
    Paes, Marciano Viana
    Lima, Flavia Regina Souza
    Gomes, Flavia Carvalho Alcantara
    BRAIN BEHAVIOR & IMMUNITY-HEALTH, 2020, 7
  • [22] Transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to animals: an updated review
    Salajegheh Tazerji, Sina
    Magalhaes Duarte, Phelipe
    Rahimi, Parastoo
    Shahabinejad, Fatemeh
    Dhakal, Santosh
    Singh Malik, Yashpal
    Shehata, Awad A.
    Lama, Juan
    Klein, Jorn
    Safdar, Muhammad
    Rahman, Md. Tanvir
    Filipiak, Krzysztof J.
    Rodriguez-Morales, Alfonso J.
    Sobur, Md. Abdus
    Kabir, Farrokhreza
    Vazir, Bita
    Mboera, Leonard
    Caporale, Marco
    Islam, Md. Saiful
    Amuasi, John H.
    Gharieb, Rasha
    Roncada, Paola
    Musaad, Sahar
    Tilocca, Bruno
    Koohi, Mohammad Kazem
    Taghipour, Ali
    Sait, Ahmet
    Subbaram, Kannan
    Jahandideh, Alireza
    Mortazavi, Pejman
    Abedini, Mohammad Amin
    Hokey, David A.
    Hogan, Unarose
    Shaheen, Mohamed N. F.
    Elaswad, Ahmed
    Elhaig, Mahmoud M.
    Fawzy, Mohamed
    JOURNAL OF TRANSLATIONAL MEDICINE, 2020, 18 (01)
  • [23] Setting up a PCR Laboratory for the Detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
    Wang, Qing-Yong
    Li, Qi
    CLINICAL LABORATORY, 2021, 67 (12) : 2613 - 2618
  • [24] Maternal and Perinatal Outcomes Associated With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection During Pregnancy, Florida, 2020-2021: A Retrospective Cohort Study
    Doyle, Timothy J.
    Kiros, Gebre Egziabhe
    Schmitt-Matzen, Emily N.
    Propper, Randy
    Thompson, Angela
    Phillips-Bell, Ghasi S.
    CLINICAL INFECTIOUS DISEASES, 2022, 75 : S308 - S316
  • [25] Relative Virulence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Among Vaccinated and Unvaccinated Individuals Hospitalized With SARS-CoV-2
    Grima, Alicia A.
    Murison, Kiera R.
    Simmons, Alison E.
    Tuite, Ashleigh R.
    Fisman, David N.
    CLINICAL INFECTIOUS DISEASES, 2023, 76 (03) : E409 - E415
  • [26] The landscape of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genomic mutations
    Lippi, Giuseppe
    Henry, Brandon M.
    JOURNAL OF LABORATORY AND PRECISION MEDICINE, 2022, 7
  • [27] Variants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Vaccine Effectiveness
    Tulimilli, SubbaRao, V
    Dallavalasa, Siva
    Basavaraju, Chaithanya G.
    Rao, Vinay Kumar
    Chikkahonnaiah, Prashanth
    Madhunapantula, SubbaRao, V
    Veeranna, Ravindra P.
    VACCINES, 2022, 10 (10)
  • [28] Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the neuroendocrine stress axis
    Steenblock, Charlotte
    Todorov, Vladimir
    Kanczkowski, Waldemar
    Eisenhofer, Graeme
    Schedl, Andreas
    Wong, Ma-Li
    Licinio, Julio
    Bauer, Michael
    Young, Allan H.
    Gainetdinov, Raul R.
    Bornstein, Stefan R.
    MOLECULAR PSYCHIATRY, 2020, 25 (08) : 1611 - 1617
  • [29] In Support of Universal Admission Testing for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) During Significant Community Transmission
    Rhee, Chanu
    Klompas, Michael
    Pak, Theodore R.
    Kohler, Julia R.
    CLINICAL INFECTIOUS DISEASES, 2024, 78 (02) : 439 - 444
  • [30] Reported Exposures Among In-Person Workers With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in 6 States, September 2020-June 2021
    Free, Hannah
    Luckhaupt, Sara E.
    Billock, Rachael M.
    Groenewold, Matthew R.
    Burrer, Sherry
    Sweeney, Marie Haring
    Wong, Jessie
    Gibb, Kathryn
    Rodriguez, Andrea
    Vergara, Ximena P.
    Cummings, Kristin J.
    Lavender, Antionette
    Argueta, Gabriel
    Crawford, Hannah-Leigh
    Erukunuakpor, Kimberly
    Karlsson, Nicole D.
    Armenti, Karla
    Thomas, Hannah
    Gaetz, Kim
    Dang, Gialana
    Harduar-Morano, Laurel
    Modji, Komi
    CLINICAL INFECTIOUS DISEASES, 2022, 75 : S216 - S224